Oops! It appears that you have disabled your Javascript. In order for you to see this page as it is meant to appear, we ask that you please re-enable your Javascript!

News

News

DuPont Opens World-Class Probiotics Fermentation Unit

ROCHESTER, N.Y., July 15, 2019 – DuPont (NYSE: DD) today announced the opening of a new state-of-the-art probiotics fermentation unit at its Rochester, New York, facility. Construction of the unit was completed in March as part of an overall $100MM investment to expand probiotics capacity. The facility is now producing high-quality probiotics for the dietary supplement and food and beverage industries, which have the potential to provide health benefits to consumers of all ages.

DuPont Chosen to Provide Probiotics for International Pediatric Sepsis Research

WILMINGTON, Del., April 25, 2019 – It is estimated that nearly 3 million newborns and 1.2 million children suffer from sepsis globally each year1, with limited effective forms of prevention currently available. To help combat this, DuPont Nutrition & Biosciences (DuPont), the global leader in probiotics, will provide clinical trial probiotic and prebiotic products to the Centre for Global Child Health at The Hospital for Sick Children (SickKids) in Toronto for its research on the effects of probiotics on sepsis in infants.

DuPont Achieves Major Milestone to Expand Probiotics Capacity

ROCHESTER, NY, March 28, 2019 – DuPont today announced it has completed construction on a new, state-of-the art probiotics fermentation unit at its Rochester, New York, facility. The unit, now largest in the world, is part of a multiphase nearly $100 million investment to expand probiotics capacity and enhance the company’s leadership in delivering high-quality, clinically documented probiotics to dietary supplement and food and beverage manufacturers.

DuPont Nutrition & Health and Lonza Specialty Ingredients Announce Joint Agreement in Human Milk Oligosaccharides

COPENHAGEN, Denmark, Feb. 27, 2019 – DuPont Nutrition & Health and Lonza Specialty Ingredients announce an agreement under which the leading biotechnology and specialty ingredient company Lonza will manufacture and supply CARE4U™ 2’-FL – a human milk oligosaccharide (HMOs). This strategic manufacturing collaboration reinforces market confidence in the supply and premium quality of this specialty ingredient.